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Oncolytic reovirus enhances rituximab-mediated antibody-
dependent cellular cytotoxicity against chronic lymphocytic
leukaemia
C Parrish1, GB Scott1, G Migneco1, KJ Scott1, LP Steele1, E Ilett1, EJ West1, K Hall1, PJ Selby1, D Buchanan2, A Varghese2, MS Cragg3,
M Coffey4, P Hillmen5, AA Melcher1 and F Errington-Mais1
The naturally occurring oncolytic virus (OV), reovirus, replicates in cancer cells causing direct cytotoxicity, and can activate innate
and adaptive immune responses to facilitate tumour clearance. Reovirus is safe, well tolerated and currently in clinical testing for
the treatment of multiple myeloma, in combination with dexamethasone/carﬁlzomib. Activation of natural killer (NK) cells has been
observed after systemic delivery of reovirus to cancer patients; however, the ability of OV to potentiate NK cell-mediated antibody-
dependent cellular cytotoxicity (ADCC) is unexplored. This study elucidates the potential of oncolytic reovirus for the treatment of
chronic lymphocytic leukaemia (CLL), both as a direct cytotoxic agent and as an immunomodulator. We demonstrate that reovirus:
(i) is directly cytotoxic against CLL, which requires replication-competent virus; (ii) phenotypically and functionally activates patient
NK cells via a monocyte-derived interferon-α (IFNα)-dependent mechanism; and (iii) enhances ADCC-mediated killing of CLL in
combination with anti-CD20 antibodies. Our data provide strong preclinical evidence to support the use of reovirus in combination
with anti-CD20 immunotherapy for the treatment of CLL.
Leukemia advance online publication, 24 April 2015; doi:10.1038/leu.2015.88
INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is the most common form of
adult leukaemia in the western world and is characterised by the
accumulation of CD19+CD5+ malignant B lymphocytes in the
blood, bone marrow and secondary lymphoid organs. Disease
stage and chromosomal aberrations are recognised to have
prognostic value, and lower levels of circulating T/natural killer
(NK) cells have also been reported to confer a poor prognosis,
suggesting a contribution of immune-mediated tumour
regulation.1
Survival from diagnosis ranges from only months to decades
and therapy is increasingly tailored to both disease and patient
factors, in particular, patients’ ﬁtness and their ability to tolerate
treatment toxicity. The chimeric monoclonal antibody, rituximab,
targets CD20, an antigen expressed on both normal and
malignant B cells, but absent from B-cell precursors, mature
plasma cells and non-lymphoid tissues.2 Rituximab has activity
against CLL as a monotherapy, but particularly impacts on
prognosis when used in combination with chemotherapy, for
example, with ﬂudarabine and cyclophosphamide, where
signiﬁcant response rates are seen in both untreated and heavily
pretreated patients (complete remission in ~ 50% of patients).
Despite such advances, CLL remains incurable and the clinical
course is characterised by persistent minimal residual disease and
the acquisition of mutations conferring drug resistance.3,4 Much of
the recent focus in CLL has been on targeting B-cell receptor and
chemokine signalling pathways, but as potent as these agents
appear, drug resistance is nonetheless emerging.4 It is therefore
critical that the anticancer armamentarium continues to expand,
focussing on targeted, low-toxicity therapies with distinct
mechanisms of action, which can be used in combination with
existing and novel agents to overcome minimal residual disease.
The activity of rituximab against B-cell malignancies is mediated
via several mechanisms including antibody-dependent cellular
cytotoxicity (ADCC) and complement-dependent cytotoxicity.5
Rituximab-mediated ADCC, encompassing antibody-dependent
cellular phagocytosis, is well characterised and roles for mono-
cytes, macrophages and NK cells have been described.6 Strategies
have been investigated to increase the efﬁcacy of rituximab-
mediated ADCC, such as disruption of killer inhibitory receptors on
NK cells, or immune activation using the immunomodulatory
agent, lenalidomide.7,8 Second- and third-generation anti-CD20
antibodies, with altered modes of action, are also under clinical
investigation,2 including ofatumumab (which induces more
potent complement-dependent cytotoxicity),9 and obinuntuzu-
mab (GA101), which has a glyco-engineered Fc portion for
enhanced ADCC.10
Oncolytic viruses (OVs) are currently being investigated for the
treatment of a range of solid malignancies and there is increasing
clinical evidence supporting their safety and efﬁcacy, both as
a monotherapy and in combination with chemotherapy or
radiotherapy.11,12 Preclinical evidence supporting clinical trial
development for OV in haematological malignancies remains
limited.13–15 Reovirus is a naturally occurring double-stranded RNA
virus, which exerts its anticancer effects by direct oncolysis and
activation of antitumour immunity.16 Reovirus activation of NK
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cells, in vitro, can increase lysis of tumour cell targets17 and has
been observed after systemic delivery to cancer patients.18
Previous literature has suggested that NK cell function is defective
in CLL patients, due to decreased production of cytolytic
granules19 and inhibitory 4-1BB/4-1BBL interactions with malig-
nant CLL cells.20
This study investigates the efﬁcacy of reovirus for the treatment
of CLL, both as a direct cytotoxic agent and as an immunomo-
dulator, and is the ﬁrst study to examine activation of NK cells by
OV in the context of CLL. The data presented clearly illustrate the
direct cytotoxic and immunomodulatory potential of reovirus, and
provide strong evidence to support the development of early-
stage clinical trials to evaluate reovirus-based combination
therapy in patients with CLL.
MATERIALS AND METHODS
Cell culture and reagents
Human CLL cell lines were purchased from German Collection of
Microorganisms and Cell Cultures (DSMZ) and were authenticated to
conﬁrm they are a perfect match to the DSMZ database. EHEB cells were
grown in RPMI (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10%
(v/v) foetal calf serum (FCS; Life Technologies, Grand Island, NY, USA)
and MEC-2 cells were grown in Iscove’s modiﬁed Dulbecco’s medium
(Sigma-Aldrich), 20% (v/v) FCS. Murine L929 cells were purchased from
American Type Culture Collection (Middlesex, UK) and grown in Dulbecco's
modiﬁed Eagle's medium (Sigma-Aldrich) containing 10% (v/v) FCS.
Routine tests ensured that all cell lines were mycoplasma free.
Peripheral blood mononuclear cells (PBMCs) were isolated from CLL
patients after written, informed consent was obtained in accordance with
local institutional ethical approval. PBMCs were isolated from whole blood
by density gradient centrifugation on Lymphoprep (Axis-Shield, Oslo,
Norway). Freshly isolated PBMCs were cultured at a high cell density
(5 × 106 cells per ml) in RPMI supplemented with 10% (v/v) FCS, as
previously described by Willmore et al.21 Primary CLL samples were
cultured as whole PBMCs immediately after collection, without freezing
cells down or isolating CLL cells from the rest of the PBMCs, which
signiﬁcantly reduced their viability. We postulate that the enhanced
viability using this culture method is because of the presence of nurse-like
cells/CD14+ monocytes, which maintain CLL viability—in support of this,
we observed a marked loss of CLL viability after removal of CD14+
monocytes from this culture system (data not shown). To investigate direct
cytotoxicity, patients with high white blood cell counts were used
(425 × 109/l), and for immune focused experiments, patients with lower
white blood cell counts were used (o25 × 109/l). Patient characteristics are
outlined in Table 1.
Reovirus type 3 dearing strain (Reolysin) was provided by Oncolytic
Biotech Inc. (Calgary, AB, Canada) and virus titre was determined by
standard plaque assay on L929 cells. For UV inactivation, a Stratalinker UV
1800 Crosslinker (Stratagene, La Jolla, CA, USA) was used and loss of viral
replication was conﬁrmed by plaque assays. Rituximab (MabThera; Roche,
Welwyn Garden City, UK) was purchased from St James’s University
Hospital (Leeds, UK). Ofatumumab and GA101 were generated in-house as
previously described from patent published sequences.22
Reovirus treatment. Patient PBMCs were cultured at 37 °C in a humidiﬁed
atmosphere and either left untreated or treated with replication-
competent or UV-inactivated reovirus, at stated multiplicities of infection
(MOIs). Different MOIs were used for direct cytotoxicity assays and immune
studies to reﬂect likely deliverable tissue doses in vivo. Lower MOI (0.1 and
1), which are achievable and deliverable to patients, were used for NK cell
experiments as NK cells should be activated almost immediately after
intravenous delivery, in the absence of viral replication. In contrast, direct
cytotoxicity is associated with in situ viral replication and as such CLL cells
are more likely to be exposed to higher MOI (1 and 10), at prolonged time
points after infection.
Cell viability
Cells were harvested, washed in FACS buffer (phosphate-buffered saline
(Sigma-Aldrich) containing 1% (v/v) FCS and 1% (v/v) sodium azide (Sigma-
Aldrich)) and cell viability determined by propidium iodide (PI, 0.05 mg/ml;
Sigma-Aldrich) staining.
Reovirus replication
Cells were treated with 1 plaque-forming unit (PFU) per cell reovirus, cells
and supernatants were harvested and subjected to three rounds of freeze–
thaw using a 37 °C water bath and methanol/dry ice. Fold increase in virus
titre was determined by comparison with input virus using plaque assay on
L929 cells.
Flow cytometry
Flow cytometry was performed using FACSCalibur (BD Biosciences, Oxford,
UK) and Attune (Life Technologies) ﬂow cytometers, and data were
analysed using Cell Quest Pro (BD Bioscience) and Attune Cytometric
software v.2.1 (Life Technologies).
Surface phenotyping. NK cells were identiﬁed as CD3−CD56+ and CLL cells
as CD19+CD5+. Expression of CD69 on NK cells, and JAM-1, HLA-Class I,
ULBP-1, ULBP-2, MICA/B, CD112, CD155 and CD20 on CLL cells, was
determined by ﬂow cytometry. Antibodies were purchased from BD
Biosciences (anti-CD69 FITC (ﬂuorescein isothiocyanate), anti-HLA-Class I
PE, anti-MICA/B PE, anti-CD112 PE, anti-CD3 PerCP and anti-CD19 FITC),
R&D Systems (Minneapolis, MN, USA; anti-ULBP-1 and -2 PE and anti-
CD155 PE), AbD Serotec (Kidlington, UK; anti-CD56 PE), Life Technologies
(anti-CD5 APC and anti-CD20 PE) and Millipore (Billerica, MA, USA; anti-
JAM-1 PE). To examine the surface binding of rituximab, CLL cells were
labelled for 30min (106 cells per ml) with different concentrations of
rituximab (at 37 °C), washed in FACS buffer and counterstained with FITC-
labelled mouse anti-human IgG antibody (BD Biosciences).
CD107a/b cytotoxicity assay. CLL patient PBMCs were treated with
reovirus overnight and cocultured with EHEB, MEC-2 or autologous CLL
targets (± rituximab or isotype control (R&D Systems)) at a 10:1 effector:
target ratio. Cells were cultured for 1 h before the addition of anti-CD3
PerCP and anti-CD107a/b FITC (BD Biosciences), anti-CD56 PE (Miltenyi
Biotec, San Diego, CA, USA) and 10 μg/ml brefeldin A (BioLegend, San
Diego, CA, USA) for 4 h. Expression of CD107a/b on CD3−CD56+ NK cells
was determined.
Intracellular IFNα. For intracellular IFNα detection, whole PBMCs, CD14+
monocyte-depleted PBMCs or isolated CD14+ monocytes (MACS CD14
positive selection; Miltenyi Biotech) were used. Isolated monocyte
preparations were 490% pure, CD14+-depleted PBMCs contained 493%
lymphocytes, compared with 80% lymphocytes in unselected PBMC
populations. Cells were subsequently treated with reovirus for 16 h before
the addition of 10 μg/ml brefeldin A for a further 5 h. Cells were washed in
FACS buffer, permeabilised in 0.3% saponin and stained with anti-IFNα PE
(BD Biosciences) for 1 h in 0.1% saponin, before ﬂow cytometry.
51Chromium release assay
PBMCs from healthy donors or CLL patients were activated with reovirus
for 16 h and their ability to lyse CLL cell targets was determined using a 4 h
51Chromium (51Cr) release assay. Brieﬂy, PBMCs were seeded at different
effector:target ratios and cocultured with 51Cr (Perkin-Elmer, Waltham, MA,
USA)-labelled EHEB/MEC-2 cell targets ( ± rituximab or isotype control) for
4 h. Cells were pelleted by centrifugation and 50 μl of supernatant was
transferred onto lumaplates (Perkin-Elmer) before analysis using a Wallac
Jet 1459 Microbeta scintillation counter and Microbeta software (Perkin-
Elmer). Percent lysis was calculated using the following formula:
% lysis = 100× (sample c.p.m.− spontaneous c.p.m.)/(maximum c.p.m.−
spontaneous c.p.m.).
IFNα neutralisation and detection
To neutralise type I IFNs, PBMCs were treated with reovirus for 16
h± neutralising antibodies (NAbs; IFN block; PBL Interferon Source,
Piscataway, NJ, USA) or isotype control (R&D Systems). IFN block consisted
of sheep polyclonal antibodies (0.75% of anti-IFN-α and -β) and mouse
monoclonal anti-human IFN-α/β receptor chain 2 (1.25%). For isotype
controls, 1.5% (v/v) sheep serum (Sigma-Aldrich) and 1.25% (v/v) mouse
IgG2a was used. Secretion of IFNα from PBMCs ( ± reovirus) was
determined by enzyme-linked immunosorbent assay (ELISA) using
matched-pair antibodies (Mabtech, Cincinnati, OH USA).
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Statistics
Statistical analysis was performed using GraphPad Prism software
(GraphPad, La Jolla, CA, USA) using paired t-tests, and one- and two-way
analysis of variance, as appropriate. Levels of statistical signiﬁcance:
*P⩽0.05, **P⩽ 0.01, ***P⩽ 0.001, ****/†P⩽ 0.0001.
RESULTS
CLL cells are susceptible to reovirus-mediated oncolysis
To investigate the potential of reovirus for the treatment of CLL
cells, the expression of the reovirus receptor (JAM-1) on CLL cell
lines (EHEB and MEC-2) and primary CLL cells from patients was
examined; EHEB/MEC-2 cell lines and all primary samples
expressed JAM-1 (Figure 1a; n= 4). Next, the direct cytotoxic
effect of reovirus was determined by PI staining: EHEB and MEC-2
cell lines were treated with reovirus for 24, 48, 72 and 96 h and the
percentage of dead cells at each time point is illustrated in
Figure 1b. The cell lines were relatively resistant to reovirus-
induced death, with only a small increase in cell death seen in
EHEB at 96 h (~20%) and no signiﬁcant cytotoxicity against MEC-2.
To conﬁrm this observation, which was unexpected in light of
previous reports,13 primary CLL samples (n= 15) were treated with
reovirus for 7 days. Toxicity was observed over this prolonged
period of infection (Figure 1c), although not at earlier time points
(data not shown); these data suggest that primary CLL cells are
susceptible to reovirus-induced death, although signiﬁcant patient
variation was observed. Use of a gating strategy to exclude cell
aggregates/doublets, before quantiﬁcation of PI+ cells, conﬁrmed
that reovirus does not cause signiﬁcant cell aggregation
(in keeping with our previous experience); hence, the reovirus-
induced toxicity illustrated in Figure 1c was not an artefact of
aggregate formation (Supplementary Figure 1).
To determine whether reovirus replication was required for the
cytotoxic effects observed, primary CLL cells were treated with live
or UV-inactivated virus for 7 days and cell viability was examined;
cytotoxicity was dependent on replication competence
Table 1. Clinical characteristics of patients donating samples
Direct killing assays (n= 9)a Degranulation assays (n= 24) Interferon-α production (n= 12)
Demographics
Age: median (range) (years) 62 (50–76) 71 (50–85) 72 (54–85)
Gender
Male 6 15 6
Female 3 9 6
Peripheral blood cell counts
Haemoglobin: median (range) (g/dl) 144 (101–158) 141 (93–163) 143.5 (130–163)
Platelets: median (range) (×109/l) 202 (118–570) 178.5 (74–308) 186.5 (131–308)
White cell count: median (range) (×109/ l) 56.9 (20.7–145.0) 17.6 (8.9–125.1) 17.4 (8.9–34.9)
Lymphocyte count: median (range) (×109/ l) 51.1 (17.4–138) 12.4 (4.7–112.7) 186.5 (131–308)
Monocyte count: median (range) (×109/ l) 0.51 (0.08–1.14) 0.47 (0.08–2.48) 0.5 (0.08–0.83)
CLL stage and prior therapy
Stage
Binet
A 7 19 12
B 2 3 0
C 0 2 0
Rai
Low (0) 6 18 11
Intermediate (1–2) 1 4 1
High (3–4) 2 2 0
Prior lines of therapy: median (range) 0 (0–1) 0 (0–3) 0 (0–1)
Prior therapy with
Fludarabine 0 1 0
Cyclophosphamide 0 1 0
Alemtuzumab 0 2 1
Rituximab 0 1 0
Corticosteroid monotherapy 1 0 0
Median time from last therapy (months)
(for previously treated patients)
28 30 30
CLL phenotype
CD20 expression
Absent 1 2 0
Weak 9 15 8
Present 0 7 4
IgH mutational status
Unmutated 1 2 1
Mutated 5 8 4
Unknown 3 14 7
TP53 status
Wild type 6 12 7
Mutated 1 1 0
Unknown 2 11 5
ATM status
Wild type 5 13 7
Mutated 2 0 0
Unknown 2 11 5
Other cytogenetic abnormalities
Del 13q14 0 5 2
Add 12 0 1 0
Normal 5 8 5
Unknown 2 8 5
Abbreviations: ATM, ataxia telangiectasia mutated; CLL, chronic lymphocytic leukaemia; IgH, immunoglobulin H. Surface expression of CD20 was determined
by ﬂow cytometry and TP53, ATM and other cytogenetic abnormalities by interphase ﬂuorescence in situ hybridisation using the Vysis LSI CLL FISH Probe Kit
(Abbott Molecular Inc., Abbott Park, IL, USA). aAdditional clinical data were unavailable for one sample.
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(Figure 1d). Reovirus replication was also conﬁrmed in susceptible
EHEB cells, and to a lower degree in reovirus-resistant MEC-2 cells
(Figure 1e); western blot analysis for the expression of the reovirus
sigma 3 protein, at 0, 3, 24, 48, 27 and 96 h after infection,
conﬁrmed reovirus protein production in both the EHEB and
MEC-2 cells, with elevated levels in the EHEB cells at earlier time
points (Supplementary Figure 2). These data corroborate the
plaque assay data and suggest that the increased sensitivity of
EHEB cells (Figure 1b) is because of increased reovirus replication.
Plaque assays conﬁrmed reovirus replication in primary CLL
patient samples, which was detectable in three of eight patient
samples (Figure 1e).
Reovirus stimulates inﬂammatory cytokine production from
tumour cells and immune effectors,23–25 which may potentially
support CLL proliferation.26 To examine this, patient PBMCs were
treated with reovirus for 7 days and expression of Ki-67 was
determined; as a positive control, CLL cells were stimulated with
αCD3/αCD28 microbeads to activate T cells and stimulate CLL
proliferation.26 Reovirus did not increase the percentage of Ki-67+
cells or CLL proliferation (Supplementary Figure 3).
Reovirus activates CLL patient NK cells and stimulates innate
antitumour immunity. It is well documented that reovirus can
exert its antitumour effects by direct oncolysis or activation of
antitumour immunity,24,25,27 hence the ability of reovirus to
stimulate immune-mediated killing of CLL was investigated.
PBMCs from healthy donors or CLL patients were isolated and
treated with 0, 0.1 or 1 PFU/cell reovirus for 16 h. In these
experiments, PBMCs, rather than isolated cell populations, were
used to allow cellular interactions that might initiate immune-
mediated cytotoxicity against malignant B cells. Reovirus activated
Figure 1. Direct cytotoxic effects of reovirus against CLL. (a) JAM-1 expression on EHEB and MEC-2 CLL cell lines (n= 2) and primary CLL
samples (n= 4). Histogram overlay plots show representative ﬂow cytometry data (shaded area= isotype; black line= JAM-1). (b) EHEB and
MEC-2 CLL cell lines were treated with different doses of reovirus and cell viability was determined by PI staining at 24, 48, 72 and 96 h after
treatment. Bar charts show the mean percentage of PI+ cells (n= 3, ± s.e.m.). (c) Primary CLL samples were treated with reovirus for 7 days and
cell viability was determined by PI staining (n= 15, ± s.e.m.). (d) Primary CLL samples were treated with live or UV-inactivated reovirus for
7 days and the percentage of PI+ cells was determined. Data shown are the mean of n= 4 independent experiments (± s.e.m.). (e) Reovirus
replication was determined in EHEB and MEC-2 cell lines (24, 48 and 72 h after infection) and primary CLL samples (7 days after infection).
Reovirus concentration was determined by plaque assay and the fold increase in viral titre was determined by comparison with input virus.
Data for EHEB and MEC-2 cells is the mean (n= 3, ± s.e.m.), and data from three primary samples where viral replication was observed
are shown.
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PBMCs to kill CLL EHEB/MEC-2 cell targets, as determined by 51Cr
release assay (Figure 2a).
NK cells are key innate immune effectors known to be
important for the efﬁcacy of rituximab- and lenalidomide-based
immunotherapy for CLL.8,28 To investigate the role of NK cells,
PBMCs from healthy donors and patient samples were incubated
with reovirus and NK cell (CD3−CD56+) activation was determined
by CD69 and CD107a/b surface expression (Figures 2b and c,
Figure 2. Cytotoxicity of reovirus-activated PBMCs against CLL. Healthy donor PBMCs and CLL patient PBMCs were isolated and either left
untreated, or treated with 0.1 or 1 PFU/cell reovirus for at least 16 h. (a) PBMCs were used in a 4 h 51Cr release assay against EHEB and MEC-2
CLL cell targets, at different effector:target (E:T) ratios. Line graphs show the mean (± s.e.m.) % lysis for healthy donors (n= 3) and patient
samples (n= 6). (b) Expression of CD69 (an early activation marker) on CD3−/CD56+ NK cells was determined. Histogram plots show
representative data for CD69 expression± reovirus treatment. Representative data are shown for healthy donors (n= 3) and patient samples
(n= 4). (c) PBMCs from healthy donors or patient samples (± reovirus) were cocultured with EHEB or MEC-2 cell targets and the expression of
CD107a/b (a marker of cytotoxic granule release) on CD3−CD56+ NK cells was determined. Bar charts show the mean percentage (± s.e.m.) of
total NK cells expressing CD107a/b for healthy donors (n= 4) and patient samples (n= 6).
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respectively). CD69 upregulation was observed after treatment
with 0.1 and 1 PFU/cell reovirus in both healthy donor and patient
samples, which correlated with increased NK cell degranulation
upon coculture with EHEB and MEC-2 cell targets. Expression of
NKG2D, DNAM-1, NKp30, NKp44 and NKp46 on donor–patient NK
cells was also examined and no reproducible changes were
observed after reovirus treatment (data not shown).
Next, to explore the mechanism of NK cell activation, we
hypothesised that reovirus-induced type 1 IFNs may be responsible
for the activation of NK cells. Figure 3a demonstrates the secretion
of IFNα, but not IFNβ (data not shown), by CLL patient PBMCs after
reovirus treatment. Moreover, blocking type 1 IFNs during reovirus
treatment completely abrogated NK cell activation, preventing
upregulation of CD69 and degranulation (Figure 3b); addition of
Figure 3. Mechanism of NK cell activation by reovirus in CLL patient samples. (a) PBMCs from CLL patients were treated with reovirus, cell-free
supernatant was collected and the secretion of IFNα was determined by ELISA. Bar chart shows mean (n= 11, ± s.e.m.). (b) CLL patient PBMCs
were either left untreated or treated with 1 PFU/cell reovirus overnight, in the presence or absence of type 1 IFN-blocking antibodies or
appropriate isotype controls. Bar charts show the mean (n= 3, ± s.e.m.) NK cell activation as determined by CD69 expression or CD107a/b
degranulation against MEC-2 targets. (c) PBMCs were treated with replication-competent (live) or UV-inactivated reovirus and (i) the
production of IFNα was determined by ELISA 24 h after treatment (n= 3, ± s.em.), (ii) the expression of CD69 on NK cells (n= 4, ± s.e.m.) and
(iii) levels of CD107 NK cell degranulation were determined (n= 4, ± s.e.m.). (d) CD14+ monocytes were isolated from CLL samples and left
overnight to allow CD14 microbeads to dissociate; monocytes were treated with reovirus and IFNα expression was determined by intracellular
ﬂow cytometry (representative of n= 2). (e–g) PBMCs from CLL patient samples were either left untreated or treated with reovirus, ±CD14+
monocyte depletion. (e) Intracellular IFNα was determined by ﬂow cytometry (representative o f n= 2). (f) Levels of IFNα secretion were
determined by ELISA (n= 5, ± s.e.m.). (g) NK cell activation was determined by CD69 expression or CD107a/b degranulation (n= 6, ± s.e.m.).
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recombinant IFNα was also sufﬁcient to activate NK cells
(CD69 upregulation and NK cell degranulation) to a level
comparable to that observed after reovirus treatment
(Supplementary Figure 4). Furthermore, we have conﬁrmed that
NK cell activation occurs independently of reovirus replication as
IFNα production (Figure 3ci), NK cell CD69 upregulation
(Figure 3cii) and NK cell degranulation (Figure 3ciii) are equivalent
with replication-competent or UV-inactivated virus (Figure 3c).
To determine the cell type responsible for IFN secretion in
response to reovirus, isolated monocytes (which can produce IFNα
in response to poly I:C)29 were positive for intracellular IFNα after
reovirus treatment (Figure 3d). Removal of CD14+ cells from
PBMCs abolished IFNα-positive cells by intracellular ﬂow cytome-
try (Figure 3e), and prevented detection of IFNα by ELISA
(Figure 3f). CD14+ depletion also prevented increased NK cell
CD69 expression and degranulation (Figure 3g), conﬁrming that
monocytes are essential for NK cell activation; however, this does
not preclude the involvement of other cell populations within the
mixed PBMC population.
Potentiating ADCC using combination viroimmunotherapy.
Although NK cell degranulation was observed after reovirus
activation of PBMCs, the levels of CLL tumour cell lysis achieved
were low, with only ~ 10% killing of EHEB and ~ 20% killing of
MEC-2 (Figure 2a). We considered whether the levels of NK cell
activatory ligands, and HLA-Class I, on CLL cells may contribute to
this low level of killing. These studies conﬁrmed that expression of
the ligands for NKG2D (ULBP-1, ULBP-2 and MICA/B) and DNAM-1
(CD112 and CD155) on CLL cell lines and primary samples was
low/absent; in contrast, signiﬁcant HLA-Class I expression was
observed (Figure 4). Preliminary investigations demonstrated that
reovirus did not alter NK cell ligand expression (data not shown).
Nevertheless, as reovirus activation of NK cells enhanced killing
of CLL cells, albeit at a low level, we investigated the addition of
rituximab (which is thought to act in part via NK cell-mediated
ADCC) to reovirus-treated PBMCs. Expression of CD20 on EHEB
and MEC-2 cells, and their ability to bind rituximab, was ﬁrst
conﬁrmed (Figure 5a). Next, the ability of NK cells from CLL
patient samples to degranulate against rituximab-opsonised cells
Figure 4. Expression of NK cell activatory ligands on CLL cells. Expression of the NK activatory ligands ULBP-1, ULBP-2, MICA/B, CD112, CD155
and HLA-Class I on EHEB, MEC-2 and patient CLL cells was determined by ﬂow cytometry. CLL cells within patient PBMCs were selected using
a double-gating strategy, gating on lymphocytes followed by CD19+CD5+ cells. Data shown are representative of n= 4 independent
experiments.
Oncolytic reovirus for the treatment of CLL
C Parrish et al
7
© 2015 Macmillan Publishers Limited Leukemia (2015) 1 – 12
(± reovirus stimulation) was investigated. Rituximab labelling of
CLL cells alone increased PBMC NK cell degranulation; however,
reovirus treatment signiﬁcantly increased NK cell CD107a/b
degranulation compared with rituximab alone (Figure 5b). 51Cr
release assays conﬁrmed that increased NK cell degranulation,
after combination treatment with reovirus and rituximab, corre-
lated with enhanced lysis of CLL cell targets (Figure 5c). In
particular, killing of EHEB cells, which were relatively resistant to
NK lysis after reovirus activation, was markedly improved using
the combination. Increased killing of isotype-labelled control cells
was observed after reovirus treatment, in the absence of
rituximab, which correlates with results shown in Figure 2. Similar
results were also observed using (i) healthy donor PBMCs as
effectors, rather than CLL patient PBMCs (Supplementary Figure 5),
Figure 5. Reovirus potentiates rituximab-mediated ADCC. (a) Representative histogram plots showing the expression of CD20, and rituximab
binding, on EHEB and MEC-2 CLL cells are shown (n= 2–3). (b) PBMCs from CLL patient samples were either left untreated or cultured
overnight with reovirus. NK cell (CD3−CD56+) CD107a/b degranulation was determined after coculture with rituximab- or isotype control-
labelled EHEB or MEC-2 cell targets. Bar charts show the mean percentage of total NK cells expressing CD107a/b (n⩾6, ± s.e.m.). (c) Four-hour
51Cr release assays were carried out using patient PBMCs that were either left untreated or activated with reovirus overnight, and cocultured
with rituximab- or isotype control-labelled EHEB or MEC-2 cell targets. Line graphs compare the mean % lysis (n= 6± s.e.m.) between 0 and
0.1 PFU/cell. Statistical signiﬁcance between 0 vs 0.1 PFU/cell for rituximab-labelled targets is shown.
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and (ii) UV-inactivated reovirus or recombinant IFNα to activate NK
cells and potentiate rituximab-mediated ADCC (Supplementary
Figure 6).
NK cells were activated by reovirus and this activation was not
impeded by the presence of malignant CLL cells. However, it was
important to address the potential of the reovirus/rituximab
combination approach in a fully autologous system. CLL cells from
patient samples express CD20 and bind rituximab (Figure 6a).
A dose-dependent increase in NK cell degranulation against
rituximab-labelled autologous CLL cells was observed (Figure 6b);
5 μg/ml rituximab was chosen for subsequent experiments.
Patient samples (n= 24) were then evaluated to test the
therapeutic potential of combining reovirus with rituximab to
potentiate NK cell-mediated ADCC of rituximab-labelled CLL cells.
NK cell degranulation against autologous CLL cells was increased
upon coculture with rituximab-labelled cells (0 PFU/cell Rit) or
activation with reovirus alone (1 PFU per cell Iso); however, the
combination of reovirus (0.1 or 1 PFU/cell) with rituximab
signiﬁcantly further increased NK cell degranulation compared
with either treatment alone (Figure 6c). Interestingly, one patient
(used for NK cell degranulation) had received prior rituximab
treatment. This patient continued to have weak CD20 expression
and NK cell degranulation was augmented in the presence of
reovirus.
Approximately 25% of the 24 patient samples did not respond
to reovirus treatment (i.e. only a small increase in NK cell
degranulation was seen). As monocytes were required for NK cell
activation, we examined whether the response to reovirus
correlated with patient absolute monocyte count ( ×109/l).
Figure 6d shows linear regression analysis of NK cell degranulation
in response to 1 PFU/cell reovirus vs patient absolute monocyte
count, this conﬁrmed a positive correlation between reovirus-
induced NK cell activation and peripheral blood monocyte levels
(P= 0.0023); a positive correlation was also observed between
reovirus/rituximab treatment and patient absolute monocyte
count (P= 0.0186, data not shown). In contrast, response to
rituximab did not correlate with monocytes levels, and NK cell
activation by reovirus did not correlate with total white blood cell
count (data not shown). Furthermore, when IFNα production from
the same samples was determined, those that responded to
reovirus treatment (i.e. increased NK cell degranulation) had greater
IFNα production (42500 pg/ml) than non-responders (o1000 pg/
ml) (Supplementary Figure 7). Monocyte counts and type I IFNα
production may therefore be useful predictors of NK cell activation
in response to reovirus treatment.
Although rituximab is a well-established therapy for CLL, other
anti-CD20 antibodies are in clinical development. To examine
whether the effects observed after reovirus/rituximab could be
Figure 6. Reovirus enhances NK cell ADCC activity against rituximab-labelled autologous CLL cell targets. (a) Expression of CD20 and
rituximab binding to CLL cells within patient PBMCs. CLL cells were identiﬁed as described in Figure 4 and data shown is representative of
n= 3 patient samples. (b) Patient PBMCs/CLL cells were labelled with increasing doses of rituximab or isotype control and cocultured with
autologous PBMCs. CD3−CD56+ NK cell CD107a/b degranulation was determined and scatter plots show the mean percentage of total NK
cells expressing CD107a/b (n= 12, ± s.e.m.). (c) Patient PBMCs were either left untreated or activated with reovirus overnight and cocultured
with rituximab/isotype-labelled autologous CLL cells. Scatter plots show CD3−CD56+ NK cell CD107a/b degranulation for each individual
sample (n= 24), mean (± s.e.m.) and comparison of 0 PFU/cell vs 0.1 and 0 vs 1 PFU/cell. (d) Linear regression analysis of reovirus-induced NK
cell activation (NK cell degranulation after treatment with 1 PFU/cell reovirus overnight, n= 24) and absolute monocyte count ( ×109/l)
demonstrating a signiﬁcant correlation (P= 0.0023). (e) Comparison of CD3−CD56+ NK cell CD107a/b degranulation after coculture with
isotype control-, ofatumumab-, rituximab- and GA101-labelled autologous CLL cells, ± reovirus activation of PBMCs, is shown (n= 7).
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translated to other anti-CD20 antibodies, where NK cells also have
a role, rituximab was compared with ofatumumab (which
stimulates more potent complement-dependent cytotoxicity6)
and GA101 (which was engineered for enhanced ADCC effector
function).30 Consistent with a paradigm in which reovirus
enhances NK ADCC effector function, all combinations enhanced
NK cell degranulation against autologous targets, with GA101/
reovirus being most effective, followed by rituximab/reovirus, and
then the ofatumumab/reovirus combination (Figure 6e).
DISCUSSION
Although previous reports have demonstrated that CLL cells are
susceptible to direct OV-mediated oncolysis,13,31 data on the
efﬁcacy of reovirus or other OV for this disease are limited.
Moreover, the immune-mediated therapeutic potential of
reovirus in CLL has not been addressed. Tumilasci et al.32 and
Samuel et al.33 reported that CLL cells were resistant to another
RNA OV, vesicular stomatitis virus (VSV), owing to overexpression
of Bcl-2, and inhibition of Bcl-2 rendered cells sensitive to VSV
oncolysis. Our work has conﬁrmed previous studies and demon-
strated that CLL cells are susceptible to reovirus-induced
oncolysis,13 although clear differences in patient susceptibility
were observed. Reovirus induces caspase-dependent apoptosis,23
hence interpatient variation in pro- vs antiapoptotic proteins, such
as Bcl-2/Bcl-xL/Bcl-w/NOXA/Mcl-1, is likely to inﬂuence virus
sensitivity. Importantly, the effect of reovirus on non-leukaemic,
haematopoietic stem cells has been previously described and no
reovirus-induced toxicity was observed.31 The limited sensitivity of
CLL cells to direct viral oncolysis has likely hampered preclinical
development of oncolytic virotherapy in this setting. However,
with increasing awareness of the immune-mediated component
of oncolytic virotherapy, it is now appropriate to reconsider the
immune potential of OV in the treatment of CLL.20,30,34
A small number of conﬂicting studies have examined NK cell
phenotype and function in CLL patients, with some suggesting NK
cell function is defective19,35 and others showing its restoration
upon cytokine activation.36,37 Often these studies focused on
isolated NK cells, ignoring the importance of the multiple cell-to-
cell interactions between immune effectors, as well as the impact
of tumour burden. In contrast, we have examined NK cell function
in the context of PBMCs and demonstrated conserved NK cell
function in CLL patient samples.
There is an increasing body of evidence supporting the clinical
efﬁcacy of OV for solid malignancies12 and preliminary data on
multiple myeloma are also encouraging.38 It is also becoming clear
that the efﬁcacy of OV is dependent on the generation of systemic
antitumour immunity, as demonstrated in numerous preclinical
in vivo models,27,34,39,40 and, for example, a phase II trial showing
regression of distant metastatic lesions following intratumoural
injection of a herpes simplex virus OV expressing granulocyte–
macrophage colony-stimulating factor (GM-CSF).41 Although
systemic delivery of OV for solid malignancies may be proble-
matic, haematological malignancies are ideally suited to systemic
viral delivery.
As reovirus is a naturally occurring double-stranded RNA virus,
to which most people have been exposed during childhood,
circulating NAbs are almost universal, and rise signiﬁcantly after
intratumoural42 or systemic treatment;43 such NAbs in the blood
could potentially impact on reovirus delivery to the tumour and its
ability to activate NK cells in vivo. However, recent studies from
our group have demonstrated that NAbs do not prevent NK cell
activation either in vitro17 or in vivo.18 Furthermore, reovirus
delivery to colorectal liver metastases, metastatic melanoma and
bone marrow-resident myeloma cells has been reported after
intravenous delivery, despite increasing NAbs levels.43–45 More-
over, it has recently been postulated that reovirus is protected
from high levels of NAbs by association with PBMCs/
granulocytes.43,46 Most signiﬁcant is the recent unexpected
observation that clearance of B16 murine melanoma after
GM-CSF/reovirus treatment was actually dependent on the
presence of anti-reovirus NAbs, monocytes and NK cells.47
Although NAbs may impede the clinical efﬁcacy of OVs in general,
clinical efﬁcacy of reovirus has been reported when used in
combination with current standard-of-care chemotherapy—a
precedent therefore exists for the use of combination regimens
to increase the in vivo efﬁcacy of reovirus in subsequent clinical
translation studies.43,48
The current study suggests absolute monocyte count and the
type 1 IFNα response could be used to predict the generation of
antitumour innate immunity by reovirus. In our series of 24
patients, ~ 25% did not respond to reovirus (i.e. NK cell activation
was not observed); when IFNα production was examined, failure
to produce IFNα and inability of NK cells to respond were
associated (Supplementary Figure 7). Furthermore, NK cell
activation also correlated with absolute monocyte count. A role
for IFNα is further supported by identiﬁcation of an IFN gene
signature within NK cells from reovirus-treated patients.18 Larger
numbers of patients, ideally within the context of a formal clinical
trial with therapeutic end points, will be needed to conﬁrm any
potential use of monocyte count as a biomarker for oncolytic
immunotherapy for CLL.
As IFNα has been reported to decrease the number of CLL cells
in the circulation at early disease stages (A and B), its production
after reovirus treatment could generate signiﬁcant bystander
effects by direct cytotoxicity as well as activation of antitumour
immunity.49,50 Cytokine production (interleukin-6 and tumour
growth factor-β) from malignant CLL cells can inhibit T and NK
cells,51–53 and PD-1/PD-1L expression may also inhibit immune cell
functions;54 future work will elucidate the effect of reovirus-
induced IFNα production on these suppressive mechanisms.
The exact mechanism of rituximab cytotoxicity in vivo remains
unclear. ADCC is thought to have a major part in the anticancer
effects of rituximab and both NK cells (via FcγR IIIa/CD16a
engagement and perforin/granzyme-mediated lysis) and myeloid
cells, such as monocytes and macrophages (via engagement of
various FcγR and phagocytosis), can be effectors for ADCC/
antibody-dependent cellular phagocytosis.55,56 Recently, a role for
neutrophils has also been implicated for non-fucosylated anti-
CD20 antibodies.57 The ability of reovirus to inﬂuence monocyte/
macrophage and neutrophil effector function, and enhance ADCC/
antibody-dependent cellular phagocytosis, is currently under
investigation.
Currently, other strategies to harness and augment antitumour
immunity are also under appraisal, for example, combination
therapy with rituximab and lenalidomide (an immunomodula-
tory agent that enhances NK cell and monocyte function8
and has single-agent efﬁcacy in CLL58) is the subject of ongoing
clinical trials.59 However, the often severe and occasionally life-
threatening toxicities associated with lenalidomide may limit
deliverability of such combinations, particularly for frail or elderly
patients.60 In addition, not all therapeutically active anti-CLL
agents are suitable for combination immunotherapy; for
example, ibrutinib can actually inhibit NK function61 and may
not be appropriate for combination with antibody therapies.
Reovirus, in contrast, offers a means of augmenting humoral
immunotherapy with minimal toxicity, and would be best utilised
to treat minimal residual disease and/or recently relapsed
patients.62
This study demonstrates that (i) CLL cells are susceptible to both
direct reovirus-induced oncolysis and reovirus-enhanced NK cell
killing, (ii) reovirus activates NK cells in CLL patient samples via an
IFNα- and CD14+ monocyte-dependent mechanism, and (iii)
reovirus together with anti-CD20 antibodies represents a promis-
ing combination strategy for the treatment of CLL. Despite
improvements in therapy, the need remains for targeted, effective,
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deliverable and minimally toxic therapies for this incurable
malignancy: reovirus in combination with anti-CD20 immunother-
apy is a rational strategy that satisﬁes all these requirements and
now warrants clinical evaluation.
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